-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
OncoSec Medical (NASDAQ:ONCS) Earns Sell Rating From Analysts at StockNews.com
OncoSec Medical (NASDAQ:ONCS) Earns Sell Rating From Analysts at StockNews.com
StockNews.com started coverage on shares of OncoSec Medical (NASDAQ:ONCS – Get Rating) in a research note released on Wednesday. The brokerage issued a sell rating on the biotechnology company's stock.
Separately, BTIG Research downgraded shares of OncoSec Medical from a buy rating to a neutral rating in a report on Monday, November 14th.
Get OncoSec Medical alerts:OncoSec Medical Stock Performance
Shares of NASDAQ:ONCS opened at $1.84 on Wednesday. The company's 50-day moving average is $8.57 and its 200 day moving average is $13.45. The company has a market capitalization of $3.32 million, a P/E ratio of -0.09 and a beta of 1.48. OncoSec Medical has a fifty-two week low of $1.77 and a fifty-two week high of $33.88.
Institutional Investors Weigh In On OncoSec Medical
An institutional investor recently raised its position in OncoSec Medical stock. Bank of New York Mellon Corp raised its holdings in shares of OncoSec Medical Incorporated (NASDAQ:ONCS – Get Rating) by 653.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 386,074 shares of the biotechnology company's stock after purchasing an additional 334,849 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.98% of OncoSec Medical worth $444,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 13.22% of the company's stock.OncoSec Medical Company Profile
(Get Rating)
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer.
Further Reading
- Get a free copy of the StockNews.com research report on OncoSec Medical (ONCS)
- MarketBeat: Week in Review 12/05 – 12/09
- There Is Fundamental Value In Broadcom, And It Yields 3.35%
- Costco vs Amazon: an end of the year showdown
- Discount Retailers Could Make Good Bargain Stocks
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com started coverage on shares of OncoSec Medical (NASDAQ:ONCS – Get Rating) in a research note released on Wednesday. The brokerage issued a sell rating on the biotechnology company's stock.
StockNews.com 开始报道的股票 OncoSec Medical（纳斯达克股票代码：ONCS — 获取评级） 在周三发布的研究报告中。该经纪公司对这家生物技术公司的股票发布了卖出评级。
Separately, BTIG Research downgraded shares of OncoSec Medical from a buy rating to a neutral rating in a report on Monday, November 14th.
另外，BTIG Research在11月14日星期一的一份报告中将OncoSec Medical的股票评级从买入下调至中性。
OncoSec Medical Stock Performance
OncoSec 医疗股票表现
Shares of NASDAQ:ONCS opened at $1.84 on Wednesday. The company's 50-day moving average is $8.57 and its 200 day moving average is $13.45. The company has a market capitalization of $3.32 million, a P/E ratio of -0.09 and a beta of 1.48. OncoSec Medical has a fifty-two week low of $1.77 and a fifty-two week high of $33.88.
纳斯达克：ONCS的股价周三开盘价为1.84美元。该公司的50天移动平均线为8.57美元，其200天移动平均线为13.45美元。该公司的市值为332万美元，市盈率为-0.09，beta值为1.48。OncoSec Medical创下五十二周低点1.77美元，五十二周高点为33.88美元。
Institutional Investors Weigh In On OncoSec Medical
机构投资者对 OncoSec Medical 进行了权衡
OncoSec Medical Company Profile
OncoSec Medical 公司简介
(Get Rating)
（获取评分）
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer.
OncoSec Medical Incorporated 是一家后期免疫肿瘤学公司，专注于设计、开发、商业化基于肿瘤内DNA的疗法，以刺激和增强治疗癌症的抗肿瘤免疫反应。该公司的产品线包括治疗晚期黑色素瘤的 KEYNOTE-695；TAVO + SARS-CoV-2 刺突糖蛋白，正在治疗 COVID-19 的 1 期临床试验中；TAVO + epacadostat + pembrolizumab，正在进行治疗鳞状细胞癌头颈癌的 1 期临床试验。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on OncoSec Medical (ONCS)
- MarketBeat: Week in Review 12/05 – 12/09
- There Is Fundamental Value In Broadcom, And It Yields 3.35%
- Costco vs Amazon: an end of the year showdown
- Discount Retailers Could Make Good Bargain Stocks
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
- 免费获取 StockNews.com 关于 OncoSec Medical (ONCS) 的研究报告的副本
- MarketBeat：本周回顾 12 月 12 日 — 2009 年 12 月
- 博通具有基本价值，其收益率为3.35％
- 好市多与亚马逊：年终对决
- 折扣零售商可以赚到不错的廉价股票
- 辉瑞、强生能否继续跑赢该指数？
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.
接收 OncoSec《医学日报》的新闻和评级 -在下面输入您的电子邮件地址，通过Marketbeat.com的免费每日电子邮件时事通讯接收OncoSec Medical及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧